Elanco Animal Health (NYSE:ELAN) Announces Earnings Results

Elanco Animal Health (NYSE:ELAN) announced its quarterly earnings data on Friday. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.07, FiscalAI reports. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The firm had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.21 billion. During the same period last year, the company posted $0.19 EPS. The business’s quarterly revenue was up 11.3% compared to the same quarter last year. Elanco Animal Health updated its Q4 2026 guidance to 0.160-0.190 EPS and its FY 2026 guidance to 1.170-1.200 EPS.

Here are the key takeaways from Elanco Animal Health’s conference call:

• Elanco reported 11% revenue growth in Q3, or 9% organic constant currency, and exceeded its guidance for revenue, adjusted EBITDA and adjusted EPS. The company raised full-year 2026 guidance, including adjusted EPS to $1.17–$1.20.
• Innovation products powered growth: Q3 innovation revenue rose 40% to $328 million, led by Zenrelia and Credelio Quattro, with both reaching record U.S. market share in September. Elanco raised its 2026 innovation revenue target to $1.275 billion and expects Befrena to be a significant U.S. Pet Health growth driver in 2027.
• Adjusted gross margin expanded 300 basis points to 56.1%, while the company generated $362 million in year-to-date free cash flow and reduced net leverage to 2.9 times. Management said productivity initiatives and growing innovation sales support further margin improvement.
• Management expects Q4 organic growth to moderate to 4%–6%, and flagged 2027 offsets including Costco’s non-renewal, regional farm-animal cycles, persistent inflation and initially dilutive Befrena growth. Elanco nevertheless reiterated its 2027 growth algorithm and expects pet health to outperform farm animal.
• Executives described competition as generally responsible but noted targeted promotions and corporate-account offers in parts of the market. They said these tactics may shift sales timing, but maintained that they do not expect a material change to the trajectory of share gains.

Elanco Animal Health Stock Up 8.3%

NYSE:ELAN traded up $1.97 during mid-day trading on Friday, reaching $25.65. The stock had a trading volume of 11,505,379 shares, compared to its average volume of 4,744,676. The stock has a market cap of $12.81 billion, a P/E ratio of -62.55, a PEG ratio of 2.14 and a beta of 1.73. The business’s 50 day moving average is $23.13 and its 200 day moving average is $23.82. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. Elanco Animal Health has a fifty-two week low of $19.40 and a fifty-two week high of $27.98.

Analyst Ratings Changes

ELAN has been the subject of a number of research analyst reports. UBS Group increased their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Jefferies Financial Group lowered shares of Elanco Animal Health from a “buy” rating to a “hold” rating and dropped their price objective for the company from $31.00 to $24.00 in a research note on Tuesday, October 20th. The Goldman Sachs Group assumed coverage on shares of Elanco Animal Health in a research report on Friday, October 16th. They issued a “buy” rating and a $32.00 target price for the company. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, September 30th. Finally, Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 4th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.33.

Elanco Animal Health News Roundup

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Third-quarter adjusted EPS was $0.27, ahead of the $0.20 consensus, while revenue rose 11% year over year to $1.265 billion, topping estimates. Elanco also reported 9% organic constant-currency growth and gross-margin expansion. Read More.
• Positive Sentiment: Elanco raised its 2026 adjusted EPS outlook to $1.17–$1.20, versus the $1.13 consensus, and revenue guidance to $5.155–$5.18 billion, above the $5.1 billion consensus. It also lifted its innovation revenue target and improved its year-end net-leverage target to about 2.9x adjusted EBITDA. Read More.
• Positive Sentiment: Company survey findings offered further demand support: 93% of pet owners surveyed said they maintained or increased pet spending in the prior three months despite cost pressures. Read More.
• Neutral Sentiment: Fourth-quarter adjusted EPS guidance of $0.16–$0.19 brackets the $0.18 consensus, while revenue guidance of $1.2 billion matches estimates. Elanco’s early 2027 outlook calls for growth broadly in line with its previously stated long-term targets, rather than a further acceleration. Read More.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Michael J. Harrington purchased 5,000 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were bought at an average price of $21.82 per share, for a total transaction of $109,100.00. Following the purchase, the director directly owned 131,451 shares in the company, valued at $2,868,260.82. This trade represents a 3.95% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Lawrence Kurzius purchased 40,000 shares of the business’s stock in a transaction dated Thursday, August 20th. The shares were acquired at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the acquisition, the director directly owned 188,647 shares in the company, valued at $4,414,339.80. This represents a 26.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 48,998 shares of company stock valued at $1,139,373 over the last three months. 1.14% of the stock is owned by insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.